VP of People Operations - Juno Therapeutics

VP of People Operations - Juno Therapeutics

August 17, 2017
August 17, 2017

Job Summary


Established in 2013, Juno Therapeutics is on a quest to radically change the course of medicine.  Using a cancer patient’s own T cells, Juno’s investigational treatments harness the power of a patient’s own immune system to treat cancer and other serious diseases. 

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. Raising one of the largest Series A investments in biotech history, with total investments of $310m, Juno made an initial public offering in December 2014.

In preparation for the anticipated commercialization of their CAR-T therapy in 2018, Juno has grown to 600 employees, and will hire another 400 in the next year, doubling over that again in the next two years. 


As the COO of the People team, you will own and lead operations to include systems/tools/automation, people and recruiting operations, training & development, employee experience and analytics.  The best candidate for the role will be obsessed with staying one step ahead of making life at Juno productive, engaging, friction-free, so employees can focus on curing cancer! 

Quick Facts

Alternate Location:San Francisco
Job Family:Human Resources
Years of Experience:15+
Reporting to:SVP, People
Company Founded:2013
Company IPO:2014
Current # Employees:600
Planned # Employees:2000

More Info


Juno Therapeutics
Hans Bishop
Business Executive, CEO
Herd Freed Hartz
Company, Executive Search Firm
City in Washington

Photos - Company Photos22

Juno Therapeutics

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[1] The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018 Juno Therapeutics was acquired by Celgene for $9 billion.[2]


Biotechnology is the use of living systems and organisms to develop or make products, or "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use" (UN Convention on Biological Diversity, Art. 2).[1] Depending on the tools and applications, it often overlaps with the (related) fields of bioengineering, biomedical engineering, biomanufacturing, molecular engineering, etc.

For thousands of years, humankind has used biotechnology in agriculture, food production, and medicine.[2] The term is largely believed to have been coined in 1919 by Hungarian engineer Károly Ereky. In the late 20th and early 21st centuries, biotechnology has expanded to include new and diverse sciences such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests.[2]

Job Documents2


Company Info - Targeted Diseases5

Company Info - Therapies5

Company Info - Key Partners7


News Articles2

Related News Coverage


Featured Locations5